Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Venturi Wealth Management LLC

Venturi Wealth Management LLC boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 229.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,725 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,899 shares during the period. Venturi Wealth Management LLC’s holdings in Jazz Pharmaceuticals were worth $336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in JAZZ. Bleakley Financial Group LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $227,000. Raymond James & Associates boosted its stake in Jazz Pharmaceuticals by 13.3% in the third quarter. Raymond James & Associates now owns 53,611 shares of the specialty pharmaceutical company’s stock valued at $5,973,000 after acquiring an additional 6,293 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 19,629 shares of the specialty pharmaceutical company’s stock valued at $2,187,000 after purchasing an additional 1,616 shares during the last quarter. Signaturefd LLC raised its position in shares of Jazz Pharmaceuticals by 273.4% during the 3rd quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 1,110 shares during the period. Finally, Private Advisor Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 238.6% in the 3rd quarter. Private Advisor Group LLC now owns 7,716 shares of the specialty pharmaceutical company’s stock worth $860,000 after purchasing an additional 5,437 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 5,053 shares of company stock valued at $617,442 over the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Piper Sandler reissued an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $180.33.

Jazz Pharmaceuticals Stock Up 1.4 %

Shares of JAZZ stock opened at $136.84 on Friday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $138.27. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business’s fifty day moving average is $124.59 and its 200-day moving average is $117.82. The stock has a market cap of $8.27 billion, a PE ratio of 19.27, a price-to-earnings-growth ratio of 1.03 and a beta of 0.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.